Montag & Associates’s Amneal Pharmaceuticals AMRX Stock Holding History

Montag & Associates’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-40,000	Closed	-$81K	–	949
2022 Q3	$81K	Hold	40,000	–	–	0.01%	465
2022 Q2	$127K	Hold	40,000	–	–	0.01%	415
2022 Q1	$167K	Hold	40,000	–	–	0.01%	410
2021 Q4	$192K	Hold	40,000	–	–	0.01%	389
2021 Q3	$214K	Hold	40,000	–	–	0.01%	375
2021 Q2	$205K	Hold	40,000	–	–	0.01%	382
2021 Q1	$269K	Hold	40,000	–	–	0.02%	347
2020 Q4	$183K	Hold	40,000	–	–	0.01%	374
2020 Q3	$155K	Hold	40,000	–	–	0.01%	297
2020 Q2	$190K	Hold	40,000	–	–	0.02%	286
2020 Q1	$139K	Hold	40,000	–	–	0.01%	273
2019 Q4	$193K	Buy	+40,000	New	+$139K	0.02%	297
2019 Q3	–	Sell	-10,000	Closed	-$72K	–	302
2019 Q2	$72K	Hold	10,000	–	–	0.01%	304
2019 Q1	$142K	Hold	10,000	–	–	0.01%	300
2018 Q4	$135K	Hold	10,000	–	–	0.01%	280
2018 Q3	$222K	Hold	10,000	–	–	0.02%	301
2018 Q2	$164K	Buy	+10,000	New	+$175K	0.02%	273

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Montag & Associates's AMRX Position: Q4 2022 in Review

Montag & Associates sold out of Amneal Pharmaceuticals (AMRX) in Q4 2022, closing a stake of 40,000 shares — an estimated $81K sold.

Montag & Associates first reported a position in AMRX in Q2 2018 and held it in 17 quarters. The position peaked at $269K in Q1 2021. 156 funds tracked by Wall St. Rank hold AMRX as of Q4 2022.

Montag & Associates reported no remaining Amneal Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Montag & Associates sold 40,000 Amneal Pharmaceuticals shares in Q4 2022, an estimated $81K.
Montag & Associates first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 17 quarters.
Montag & Associates's Amneal Pharmaceuticals position peaked at $269K in Q1 2021.
156 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2022.

Based on Montag & Associates's 13F filing for Q4 2022, filed 2 Feb 2023.